PLEKHA2

Across TCGA pan-cancer cohorts, PLEKHA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PLEKHA2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PLEKHA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLEKHA2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

GBM, CCRCC, and PDAC are the cancer types where PLEKHA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.519	0.882	<.001	28	view →
CCRCC	DFS	Median	III,IV	0.988	0.730	.005	17	view →
PDAC	OS	Tertile	III,IV	0.264	0.778	.002	11	view →
LUAD	DFS	Quartile	All	0.782	0.445	.004	8	view →
HNSC	DFS	Tertile	IV	1.000	0.883	.026	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PLEKHA2–GBM (DFS)

Open the GBM breakdown →